Gali Health, a health technology company working to advance personalized medicine, today announced that it is making the Gali AI-powered personal health assistant for people with chronic conditions available to a broader initial group of users.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190620005139/en/
Gali Health is making its Gali AI-powered mobile personal health assistant available to a broader initial group of users who live with inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis. New users are invited to join the Gali community in stages through a waitlist that can be accessed on the company’s website. Gali relies on individual health information and collective intelligence to help people with chronic conditions proactively manage their health. (Photo: Business Wire)
The wider release follows successful completion and processing of feedback gathered from inflammatory bowel diseases (IBD) patient advocates during the Limited Access Program implemented in spring of 2019. Expanding the user base will allow Gali to continue evolving with help from more members of the IBD community. “Seeing my ideas and feedback come to life within the Gali app is more than rewarding. Each design change leads to further feedback and a better user experience. It’s an honor to help develop a platform built by patients for patients,” says Gali Health Ambassador and IBD patient advocate Molly Dunham-Friel.
Gali Health is inviting new users to join the Gali community in stages through a waitlist that can be found on its website. The waitlist is open to anyone who lives with IBD. “Our Ambassadors, who were the first to use Gali regularly, provided us with invaluable insights into their personal health journeys. They helped to validate our approach and bring us to a point where Gali is ready to keep learning,” says Ilya Kupershmidt, CEO and founder of Gali Health.
The wider release is enabled by Gali Health having secured over $2 million in seed funding from top investors in biotech, consumer products and genomics. This round is led by Felicis Ventures and includes other prominent institutional investors such as Civilization Ventures and Bold Capital Partners, as well as angel investors Mostafa Ronaghi and Robert Nelsen. The funding enables Gali to accelerate its development and precision medicine-focused R&D efforts.
Gali Health plans to release the Gali intelligent health assistant to the general public in the fall of 2019.
About Gali Health
At Gali Health, we are on a mission to make sure nobody ever feels isolated, lost or powerless in the face of existing or potential disease. We are a San Francisco-based health tech company working to advance precision medicine by crowdsourcing personal health data and medically-validated insights, applying AI to process them and providing highly personalized informational support on the medical, lifestyle and psychological aspects of living with chronic disease. Our mobile personal health assistant named Gali relies on individual health information and collective intelligence to help people with chronic conditions proactively manage their health. For more information, please visit galihealth.com.